CTIS2023-508747-49-00进行中（未招募）1 期
UECHUP-ALM/23-6
Qualix Pharma S.L.0 个研究点目标入组 28 人开始时间: 2023年12月19日最近更新:
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 28
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 64（—）
- 性别
- All
入选标准
- 未提供
排除标准
- 未提供
研究者
相似试验
进行中（未招募）
1 期
RANDOMISED, CROSSOVER BIOEQUIVALENCE CLINICAL TRIAL OF APIXABAN 5 MG CAPSULES VS APIXABAN 5 MG FILM-COATED TABLETS, AFTER A SINGLE ORAL DOSE ADMINISTRATION TO HEALTHY VOLUNTEERS UNDER FASTING CONDITIONS.thrombosisCTIS2023-506035-15-00aboratorios Alter S.A.36
进行中（未招募）
1 期
Randomised, crossover bioequivalence clinical trial of apixaban 5 mg film-coated tablets, after a single oral dose administration to healthy volunteers under fasting conditionsCTIS2023-503557-35-00Alter Farmacia S.A.24
进行中（未招募）
1 期
An open label, balanced, randomized, single dose, two treatment, two period, two sequence, crossover, bioequivalence study comparing Lacosamide tablets USP 200 mg, manufactured by Sun Laboratories Industries Limited, India with Vimpat (Lacosamide) 200 mg film-coated tablets, Marketing Authorisation Holder UCB Pharma S.A., Belgium, in healthy adult, human subjects under fasting condition.Epileptic seizuresCTIS2023-507991-32-00Sun Pharmaceutical Industries Limited32
进行中（未招募）
1 期
Randomised, crossover bioequivalence clinical trial of montelukast 10 mg capsules vs montelukast 10 mg film-coated tablets, after a single oral dose administration to healthy volunteers under fasting conditions.AsthmaCTIS2023-506937-30-00aboratorios Alter S.A.36
进行中（未招募）
1 期
A study to characterize the safety, efficacy, pharmacokinetics of subcutaneous administration of ABBV-383 in patients with relapsed or refractory Multiple MyelomaCTIS2023-507901-32-00AbbVie Deutschland GmbH & Co. KG55